# Precede Biosciences Shares ESMO 2026 Data on Prostate Cancer Therapy Response

> Precede Biosciences reveals molecular states linked to PSMA therapy success and resistance in advanced prostate cancer.
- Title: Precede Biosciences Shares ESMO 2026 Data on Prostate Cancer…
- Summary: Precede Biosciences reveals molecular states linked to PSMA therapy success and resistance in advanced prostate cancer. Precede Biosciences' plasma profiling…
- Keywords: precede biosciences, esmo 2026, prostate cancer, psma-directed radioligand therapy, mcrpc, liquid biopsy, tumor biology, money, business, Precede, Biosciences, Shares
- Source: Financial Post — https://financialpost.com/globe-newswire/precede-biosciences-presents-esmo-2026-data-revealing-biology-associated-with-response-and-resistance-to-psma-directed-radioligand-therapy-in-advanced-prostate-cancer
- Author: GlobeNewswire
- Published: 2026-10-23T13:16:23+00:00
- Read time: 1 min
- Topics: precede biosciences, esmo 2026, prostate cancer, psma-directed radioligand therapy, mcrpc, liquid biopsy, tumor biology, money, business
## Study Finds Three Molecular States
Baseline plasma profiling identified three molecular states previously characterized in tissue: androgen receptor (AR)-high/metabolic, stem/epithelial-mesenchymal transition (EMT), and AR-low/proliferative.
## AR-High Group Shows Best Outcomes
The AR-high/metabolic group showed the most favorable outcome trends among the three molecular states.
## Gene Set Analysis Confirms Patterns
Analysis of published gene sets corroborated findings: higher stem-like and WNT signaling activity linked to shorter time to next treatment.
## AR Signaling Linked to Longer Treatment
Higher AR signaling and luminal A activity associated with longer time to next treatment in metastatic castration-resistant prostate cancer.
## PSMA Expression Declines at Progression
At progression, plasma-predicted expression of therapeutic targets including PSMA declined in 11 of 17 patients.
## Company Presents ESMO 2026 Data
Precede Biosciences announced new data being presented at ESMO 2026 Congress in Madrid, Spain from October 23-27, 2026.
## Treatment Sequencing Strategies
The findings support investigation of treatment-sequencing strategies involving alternative PSMA-targeting modalities and therapies directed at other targets.
## Key takeaway

Precede Biosciences' plasma profiling shows three molecular states predicting response to PSMA therapy in advanced prostate cancer.